904 related articles for article (PubMed ID: 29562260)
1. Towards an optimal luteal support modality in agonist triggered cycles: a randomized clinical trial.
Elgindy EA; Sibai H; Mostafa MI; Gibreel A; Darwish E; Maghraby H
Hum Reprod; 2018 Jun; 33(6):1079-1086. PubMed ID: 29562260
[TBL] [Abstract][Full Text] [Related]
2. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
[TBL] [Abstract][Full Text] [Related]
3. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
[TBL] [Abstract][Full Text] [Related]
4. The freeze-all strategy versus agonist triggering with low-dose hCG for luteal phase support in IVF/ICSI for high responders: a randomized controlled trial.
Santos-Ribeiro S; Mackens S; Popovic-Todorovic B; Racca A; Polyzos NP; Van Landuyt L; Drakopoulos P; de Vos M; Tournaye H; Blockeel C
Hum Reprod; 2020 Dec; 35(12):2808-2818. PubMed ID: 32964939
[TBL] [Abstract][Full Text] [Related]
5. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology.
Youssef MA; Van der Veen F; Al-Inany HG; Mochtar MH; Griesinger G; Nagi Mohesen M; Aboulfoutouh I; van Wely M
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD008046. PubMed ID: 25358904
[TBL] [Abstract][Full Text] [Related]
6. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
[TBL] [Abstract][Full Text] [Related]
7. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial.
Andersen CY; Elbaek HO; Alsbjerg B; Laursen RJ; Povlsen BB; Thomsen L; Humaidan P
Hum Reprod; 2015 Oct; 30(10):2387-95. PubMed ID: 26209535
[TBL] [Abstract][Full Text] [Related]
8. GnRH agonist versus HCG triggering in different IVF/ICSI cycles of same patients: a retrospective study.
Yılmaz N; Ceran MU; Ugurlu EN; Gülerman HC; Engin Ustun Y
J Obstet Gynaecol; 2020 Aug; 40(6):837-842. PubMed ID: 31791167
[TBL] [Abstract][Full Text] [Related]
9. Ovulation triggering with hCG alone, GnRH agonist alone or in combination? A randomized controlled trial in advanced-age women undergoing IVF/ICSI cycles.
Zhou C; Yang X; Wang Y; Xi J; Pan H; Wang M; Zhou Y; Xiao Y
Hum Reprod; 2022 Jul; 37(8):1795-1805. PubMed ID: 35595223
[TBL] [Abstract][Full Text] [Related]
10. HCG (1500IU) administration on day 3 after oocytes retrieval, following GnRH-agonist trigger for final follicular maturation, results in high sufficient mid luteal progesterone levels - a proof of concept.
Haas J; Kedem A; Machtinger R; Dar S; Hourvitz A; Yerushalmi G; Orvieto R
J Ovarian Res; 2014 Apr; 7():35. PubMed ID: 24694069
[TBL] [Abstract][Full Text] [Related]
11. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
[TBL] [Abstract][Full Text] [Related]
12. Endometrial gene expression in the early luteal phase is impacted by mode of triggering final oocyte maturation in recFSH stimulated and GnRH antagonist co-treated IVF cycles.
Humaidan P; Van Vaerenbergh I; Bourgain C; Alsbjerg B; Blockeel C; Schuit F; Van Lommel L; Devroey P; Fatemi H
Hum Reprod; 2012 Nov; 27(11):3259-72. PubMed ID: 22930004
[TBL] [Abstract][Full Text] [Related]
13. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.
Seyhan A; Ata B; Polat M; Son WY; Yarali H; Dahan MH
Hum Reprod; 2013 Sep; 28(9):2522-8. PubMed ID: 23633553
[TBL] [Abstract][Full Text] [Related]
14. Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS.
Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC
Hum Reprod; 2013 Jul; 28(7):1929-42. PubMed ID: 23624582
[TBL] [Abstract][Full Text] [Related]
15. Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist Protocol.
Griesinger G; Verweij PJ; Gates D; Devroey P; Gordon K; Stegmann BJ; Tarlatzis BC
PLoS One; 2016; 11(3):e0149615. PubMed ID: 26950065
[TBL] [Abstract][Full Text] [Related]
16. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles.
Youssef MA; Van der Veen F; Al-Inany HG; Griesinger G; Mochtar MH; van Wely M
Cochrane Database Syst Rev; 2010 Nov; (11):CD008046. PubMed ID: 21069701
[TBL] [Abstract][Full Text] [Related]
17. [GnRH agonist triggering in IVF and luteal phase support in women at risk of ovarian hyperstimulation syndrome].
Guivarc'h-Levêque A; Jaffré F; Homer L; Moy L; Priou G; Colleu D; Denis I; Arvis P
Gynecol Obstet Fertil; 2013 Sep; 41(9):511-4. PubMed ID: 23972925
[TBL] [Abstract][Full Text] [Related]
18. Reproductive Outcome After GnRH Agonist Triggering With Co-Administration of 1500 IU hCG on the Day of Oocyte Retrieval in High Responders: A Long-Term Retrospective Cohort Study.
Abdulkhalikova D; Bokal EV; Stimpfel M; Ciglar P; Korosec S
Front Endocrinol (Lausanne); 2022; 13():826411. PubMed ID: 35464066
[TBL] [Abstract][Full Text] [Related]
19. Luteal granulosa cells from natural cycles are more capable of maintaining their viability, steroidogenic activity and LH receptor expression than those of stimulated IVF cycles.
Bildik G; Akin N; Seyhan A; Esmaeilian Y; Yakin K; Keles I; Balaban B; Ata B; Urman B; Oktem O
Hum Reprod; 2019 Feb; 34(2):345-355. PubMed ID: 30520979
[TBL] [Abstract][Full Text] [Related]
20. Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.
Engmann LL; Maslow BS; Kaye LA; Griffin DW; DiLuigi AJ; Schmidt DW; Grow DR; Nulsen JC; Benadiva CA
J Ovarian Res; 2019 Jan; 12(1):8. PubMed ID: 30684970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
